InfuSystem Holdings, Inc. (INFU)

Recent Quarterly Results

Source: Company filings

Price Chart

InfuSystem Holdings, Inc. (INFU) stock price: $7.95 (+0.00, +0.00%)

Why Bull

• •Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its growth potential.
• •Community sentiment has turned positive, with discussions highlighting the company's strong position in the healthcare services sector.
• •New contracts and partnerships announced in the last month have bolstered investor optimism about revenue growth.
• •Analysts have noted an increasing demand for healthcare solutions, positioning InfuSystem favorably in a growing market.

Why Bear

• •Concerns over potential regulatory changes in the healthcare industry have raised uncertainties among investors.
• •Social media sentiment has shown some skepticism, with discussions around competition and market share erosion affecting confidence.
• •Recent earnings reports have not met some expectations, leading to questions about the company's operational efficiency.
• •Overall market volatility has made investors cautious, causing some to reassess their positions in InfuSystem.

• Prestige Consumer Healthcare (PBH) Q3 Earnings Lag Estimates
  Yahoo! Finance: INFU News · Feb 5, 2026
• Prestige Consumer Healthcare (PBH) Q3 Earnings Lag Estimates
  Zacks · Feb 5, 2026
• InfuSystem: Regulatory Backed Market Catalyst
  seekingalpha.com · Jan 30, 2026
• Earnings Scheduled For November 4, 2025
  benzinga · Nov 4, 2025

Rationale

AI-generated technical analysis for INFU including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Set your price target for InfuSystem Holdings, Inc. (INFU), choose a timeframe, and track your prediction accuracy.

Current price: $7.95

No insider trades in the last 30 days.

Score Factors

• Revenue Growth 4/100

  Revenue grew only 7.2% YoY, suggesting the company is in a slower growth phase.

• Gross Margin 8/100

  Gross margin at 55.4% indicates good unit economics and healthy profitability per sale.

• Operating Leverage 4/100

  Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

• Cash Runway 5/100

  Cash position data is currently unavailable for this company.

• R&D Intensity 5/100

  R&D spending data is currently unavailable for this company.

• Insider Activity 6/100

  No significant insider buying or selling recently, which is neutral for the stock outlook.

• Short Interest 5/100

  Float and volume data unavailable for liquidity analysis.

• Price Momentum 0/100

  No bullish technical signals detected. The stock lacks upward price momentum currently.

• News Sentiment 5/100

  No sentiment data available

What does this score mean?

The MoonshotScore rates INFU's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

What does InfuSystem Holdings, Inc. do?

InfuSystem Holdings, Inc. operates as a leading provider of infusion pumps and related products and services in the United States and Canada. The company focuses on supplying electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics. Additionally, InfuSystem provides durable medical equipment services, including the sale, rental, and leasing of new and pre-owned infusion pumps, along with biomedical recertification, maintenance, and repair services. The company serves a diverse range of healthcare settings, ensuring comprehensive support for its clients.

Is INFU stock a good buy?

InfuSystem Holdings presents a mixed investment profile. The company's specialized focus on infusion therapy and durable medical equipment, coupled with a gross margin of 55.4%, suggests potential for growth. However, the relatively small market capitalization of $0.16 billion and a profit margin of 3.9% indicate potential risks. Investors should carefully consider the company's growth opportunities, competitive landscape, and financial performance before making an investment decision. The P/E ratio of 29.04 should be evaluated in the context of industry peers and future earnings growth expectations.

What are the main risks for INFU?

InfuSystem faces several risks, including intense competition from larger medical device companies, which could erode market share and pricing power. Regulatory changes and pricing pressures in the healthcare industry could also impact profitability. Additionally, the company faces the risk of technological obsolescence, which could render its existing products outdated. An economic downturn affecting healthcare spending could reduce demand for infusion services, impacting revenue and earnings. Investors should carefully assess these risks before investing in INFU.

Is INFU a good stock to buy?

Whether INFU is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the INFU MoonshotScore?

The MoonshotScore for INFU is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is INFU data updated?

INFU stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to INFU is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for INFU?

Growth catalysts for InfuSystem Holdings, Inc. (INFU) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes InfuSystem Holdings, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are INFU's main competitors?

InfuSystem Holdings, Inc. (INFU) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether INFU has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about INFU?

Wall Street analyst coverage for INFU includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is INFU's market cap?

Market capitalization (market cap) for INFU is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows INFU's current market cap alongside enterprise value and other valuation metrics.

How has INFU stock performed recently?

INFU's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing INFU's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in INFU?

Key risk categories for INFU include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures INFU's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling INFU?

Insider trading activity for INFU tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is INFU a good stock for beginners?

InfuSystem Holdings, Inc. (INFU) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is INFU for first-time investors?

Every stock carries risk, including InfuSystem Holdings, Inc. (INFU). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like INFU.